Loading
Life sciences · Journal article
International Science Journal · October 31, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Colorectal peritoneal metastases represent a challenging manifestation of advanced colorectal cancer, characterized by heterogeneous tumor distribution, limited therapeutic accessibility, and variable oncological outcomes. Advances in cytoreductive surgery and intraperitoneal treatment strategies have transformed the management of selected patients; however, controversies persist regarding surgical eligibility, the additional benefit of hyperthermic intraperitoneal chemotherapy (HIPEC), and the optimal integration of systemic therapies. This narrative review critically examines international scientific evidence concerning patient selection, prognostic determinants, cytoreductive surgery, intraperitoneal therapeutic approaches, and oncological outcomes, incorporating the Latin American perspective. Evidence from randomized clinical trials, observational studies, systematic reviews, prognostic investigations, and international consensus recommendations was evaluated through a descriptive and comparative analytical framework. The findings identified completeness of cytoreduction, peritoneal tumor burden, anatomical resectability, and selected clinical and molecular characteristics as important determinants of survival. The PRODIGE 7 trial demonstrated comparable median overall survival following cytoreductive surgery with and without oxaliplatin-based HIPEC (41.7 versus 41.2 months), while severe postoperative adverse events at 60 days were more frequent in the combined-treatment group (26% versus 15%). Prognostic meta-analyses consistently associated incomplete cytoreduction and increasing Peritoneal Cancer Index with unfavorable survival outcomes. Emerging approaches, including pressurized intraperitoneal aerosol chemotherapy, demonstrated preliminary clinical activity, although their long-term survival benefits remain uncertain. Latin American institutional experience highlighted regional advances alongside persistent differences in access to specialized oncological care. Overall, the evidence supports individualized patient selection, complete macroscopic cytoreduction when feasible, and multidisciplinary treatment planning as fundamental principles of management. Further prospective investigations are required to clarify the role of alternative intraperitoneal regimens, integrate molecular prognostic models, and improve oncological outcomes across diverse healthcare settings.